On January 3, 2023 Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET) (Press release, Scholar Rock, JAN 3, 2023, View Source [SID1234625776]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

On January 3, 2023 -PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 (Press release, PharmaEssentia, JAN 3, 2023, View Source [SID1234625775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A link to the live audio webcast of the presentation will be available on the News page of the PharmaEssentia USA website at us.pharmaessentia.com. An audio replay will be available for 30 days following the presentation.

On January 3, 2023 Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, reported that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Thursday, Jan. 12, 2023, at 12 p.m., PST and will be made available to attendees and the general public (Press release, Quanterix, JAN 3, 2023, View Source [SID1234625774]). In addition to the session, the company will also be hosting one-on-one meetings with institutional investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information
To access the live audio webcast of Quanterix’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 12, 2023 at 12 p.m., PST, please visit: View Source;kiosk=true.

Replays of the webcasts will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of Quanterix’s website.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa technology, visit: View Source

On January 3, 2023 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, reported that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT (Press release, Rocket Pharmaceuticals, JAN 3, 2023, View Source [SID1234625773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available under "Events" in the Investors section of the Company’s website at View Source The webcast replay will be available on the Rocket website following the conference.

On January 3, 2023 Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher"), the world leader in serving science, reported that it has completed its acquisition of The Binding Site Group ("The Binding Site"), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates (Press release, Thermo Fisher Scientific, JAN 3, 2023, View Source [SID1234625772]). Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very excited to welcome The Binding Site colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "The Binding Site expands our existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. Early diagnosis and well-informed treatment decisions can make a significant difference in patient outcomes, and we are excited by the opportunity to enable further advancements in this area for the benefit of patients."

The Binding Site has more than 1,200 employees globally and will become part of Thermo Fisher’s Specialty Diagnostics segment.

Serving clinicians and laboratory professionals worldwide, The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite offering is widely recommended for multiple myeloma diagnosis and monitoring across all stages of the disease by major clinical guideline publications.

The transaction is expected to be accretive to adjusted earnings per share by $0.07 in 2023.1